{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:34:24Z","timestamp":1787315664588,"version":"build-2736575974"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To analyze the clinical features of refractory age-related macular degeneration patients associated with the response to three consecutive loading doses of anti\u2013vascular endothelial growth factor.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A retrospective chart review was performed on typical exudative age-related macular degeneration patients treated by three consecutive anti\u2013vascular endothelial growth factor injections. The patients were divided into a group without residual fluid on optical coherence tomography images (Group 1) and a group with residual fluid (Group 2). We analyzed qualitative and quantitative morphologic features of optical coherence tomography and optical coherence tomography angiography. We performed univariate and multivariate logistic regression analyses to identify factors associated with the treatment response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      We enrolled a total of 90 patients (Group 1: n = 60, Group 2: n = 30). Under optical coherence tomography, the choroidal thickness differed significantly between groups 1 and 2 (246.60 \u00b1 67.67 vs. 286.90 \u00b1 40.92\n                      <jats:italic toggle=\"yes\">\u00b5<\/jats:italic>\n                      m,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.001). Under optical coherence tomography angiography, the presence of branching (48.3% vs. 73.3%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.024), loops (31.7% vs. 66.7%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.002), and a peripheral arcade (40.0% vs. 76.7%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.001) differed significantly. Logistic regression analysis showed that the initial CT (B = 0.012;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.007), presence of loops (B = 1.289;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.015), and peripheral arcade (B = 1.483;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.008) significantly affected the anti\u2013vascular endothelial growth factor treatment response.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>A thicker choroid and the presence of loops and a peripheral arcade were significantly associated with a poorer response to three loading anti\u2013vascular endothelial growth factor injections in typical exudative age-related macular degeneration patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/iae.0000000000003628","type":"journal-article","created":{"date-parts":[[2022,9,26]],"date-time":"2022-09-26T16:01:12Z","timestamp":1664208072000},"page":"8-15","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":8,"title":["CHARACTERISTICS OF AGE-RELATED MACULAR DEGENERATION SHOWING A POOR RESPONSE TO THREE LOADING DOSES OF ANTI\u2013VASCULAR ENDOTHELIAL GROWTH FACTOR"],"prefix":"10.1097","volume":"43","author":[{"given":"Yong-Yeon","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Ho","family":"Jun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung-Tae","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Chul","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5614-077X","authenticated-orcid":false,"given":"Min-Woo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250605","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.ophtha.2019.11.004","article-title":"Consensus nomenclature for reporting neovascular age-related macular degeneration data: consensus on neovascular age-related macular degeneration nomenclature study group","volume":"127","author":"Spaide","year":"2020","journal-title":"Ophthalmology"},{"key":"R2-20250605","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","article-title":"Ranibizumab and bevacizumab for neovascular age-related macular degeneration","volume":"364","author":"Group","year":"2011","journal-title":"N Engl J Med"},{"key":"R3-20250605","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.preteyeres.2015.07.007","article-title":"A paradigm shift in imaging biomarkers in neovascular age-related macular degeneration","volume":"50","author":"Schmidt-Erfurth","year":"2016","journal-title":"Prog Retin Eye Res"},{"key":"R4-20250605","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/IAE.0000000000000645","article-title":"Correlation between optical coherence tomographic hyperreflective foci and visual outcomes after anti-VEGF treatment in neovascular age-related macular degeneration and polypoidal choroidal vasculopathy","volume":"36","author":"Lee","year":"2016","journal-title":"Retina"},{"key":"R5-20250605","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.preteyeres.2017.11.003","article-title":"Optical coherence tomography angiography","volume":"64","author":"Spaide","year":"2018","journal-title":"Prog Retin Eye Res"},{"key":"R6-20250605","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1001\/jamaophthalmol.2015.1320","article-title":"Association of choroidal neovascularization and central serous chorioretinopathy with optical coherence tomography angiography","volume":"133","author":"Bonini Filho","year":"2015","journal-title":"JAMA Ophthalmol"},{"key":"R7-20250605","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/j.ophtha.2015.01.029","article-title":"Spectral-domain optical coherence tomography angiography of choroidal neovascularization","volume":"122","author":"de Carlo","year":"2015","journal-title":"Ophthalmology"},{"key":"R8-20250605","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1016\/j.ophtha.2014.01.034","article-title":"Quantitative optical coherence tomography angiography of choroidal neovascularization in age-related macular degeneration","volume":"121","author":"Jia","year":"2014","journal-title":"Ophthalmology"},{"key":"R9-20250605","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1038\/eye.2015.80","article-title":"OCT angiography and sequential quantitative analysis of type 2 neovascularization after ranibizumab therapy","volume":"29","author":"Kuehlewein","year":"2015","journal-title":"Eye (Lond)"},{"key":"R10-20250605","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.ajo.2015.06.030","article-title":"Optical coherence tomography angiography of type 1 neovascularization in age-related macular degeneration","volume":"160","author":"Kuehlewein","year":"2015","journal-title":"Am J Ophthalmol"},{"key":"R11-20250605","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1097\/IAE.0000000000000835","article-title":"Optical coherence tomography angiography of type 3 neovascularization secondary to age-related macular degeneration","volume":"35","author":"Kuehlewein","year":"2015","journal-title":"Retina"},{"key":"R12-20250605","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/IAE.0000000000001628","article-title":"Biomarkers of neovascular activity in age-related macular degeneration using optical coherence tomography angiography","volume":"38","author":"Al-Sheikh","year":"2018","journal-title":"Retina"},{"key":"R13-20250605","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s00417-019-04546-1","article-title":"Hyperreflective foci in predicting the treatment outcome of antivascular endothelial growth factor in neovascular age-related macular degeneration","volume":"258","author":"Hsia","year":"2020","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R14-20250605","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1016\/j.ophtha.2015.05.042","article-title":"Subretinal hyperreflective material in the comparison of age-related macular degeneration treatments trials","volume":"122","author":"Willoughby","year":"2015","journal-title":"Ophthalmology"},{"key":"R15-20250605","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1097\/IAE.0000000000000766","article-title":"Optical coherence tomography angiography versus traditional multimodal imaging in assessing the activity of exudative age-related macular degeneration: a new diagnostic challenge","volume":"35","author":"Coscas","year":"2015","journal-title":"Retina"},{"key":"R16-20250605","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"N Engl J Med"},{"key":"R17-20250605","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1056\/NEJMoa062655","article-title":"Ranibizumab versus verteporfin for neovascular age-related macular degeneration","volume":"355","author":"Brown","year":"2006","journal-title":"N Engl J Med"},{"key":"R18-20250605","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/j.ophtha.2011.12.016","article-title":"HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration","volume":"119","author":"Singer","year":"2012","journal-title":"Ophthalmology"},{"key":"R19-20250605","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1038\/eye.2011.224","article-title":"Outcome of ranibizumab treatment in neovascular age related macula degeneration in eyes with baseline visual acuity better than 6\/12","volume":"25","author":"Williams","year":"2011","journal-title":"Eye (Lond)"},{"key":"R20-20250605","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1016\/j.ophtha.2013.01.073","article-title":"Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials","volume":"120","author":"Jaffe","year":"2013","journal-title":"Ophthalmology"},{"key":"R21-20250605","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.ophtha.2010.12.019","article-title":"Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study","volume":"118","author":"Holz","year":"2011","journal-title":"Ophthalmology"},{"key":"R22-20250605","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ophtha.2013.08.011","article-title":"Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies","volume":"121","author":"Schmidt-Erfurth","year":"2014","journal-title":"Ophthalmology"},{"key":"R23-20250605","doi-asserted-by":"crossref","first-page":"523","DOI":"10.3928\/23258160-20150521-03","article-title":"Relationship between subretinal hyperreflective material reflectivity and volume in patients with neovascular age-related macular degeneration following anti-vascular endothelial growth factor treatment","volume":"46","author":"Charafeddin","year":"2015","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"R24-20250605","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1097\/IAE.0000000000001748","article-title":"Prognostic value of subretinal hyperreflective material in neovascular age-related macular degeneration treated with bevacizumab","volume":"38","author":"Pokroy","year":"2018","journal-title":"Retina"},{"key":"R25-20250605","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/IAE.0000000000002845","article-title":"Topographic changes in choroidal thickness in age-related macular degeneration during the development of active choroidal neovascularization","volume":"41","author":"Park","year":"2021","journal-title":"Retina"},{"key":"R26-20250605","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.ajo.2014.01.019","article-title":"Subfoveal choroidal thickness as a potential predictor of visual outcome and treatment response after intravitreal ranibizumab injections for typical exudative age-related macular degeneration","volume":"157","author":"Kang","year":"2014","journal-title":"Am J Ophthalmol"},{"key":"R27-20250605","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1136\/bjophthalmol-2018-313065","article-title":"Optical coherence tomography angiography in exudative age-related macular degeneration: a predictive model for treatment decisions","volume":"103","author":"Coscas","year":"2019","journal-title":"Br J Ophthalmol"},{"key":"R28-20250605","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ajo.2015.04.012","article-title":"Optical coherence tomography angiography signs of vascular abnormalization with antiangiogenic therapy for choroidal neovascularization","volume":"160","author":"Spaide","year":"2015","journal-title":"Am J Ophthalmol"},{"key":"R29-20250605","doi-asserted-by":"crossref","first-page":"19240","DOI":"10.1038\/s41598-019-55871-8","article-title":"Predictors of neovascular activity during neovascular age-related macular degeneration treatment based on optical coherence tomography angiography","volume":"9","author":"Bae","year":"2019","journal-title":"Sci Rep"},{"key":"R30-20250605","doi-asserted-by":"crossref","first-page":"e240","DOI":"10.1111\/aos.14554","article-title":"Profiling neovascular age-related macular degeneration choroidal neovascularization lesion response to anti-vascular endothelial growth factor therapy using SSOCTA","volume":"99","author":"Told","year":"2021","journal-title":"Acta Ophthalmol"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000003628","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T13:06:40Z","timestamp":1749128800000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000003628"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000003628","relation":{},"ISSN":["0275-004X"],"issn-type":[{"value":"0275-004X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"2022-05-12","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-09-17","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}